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http://dx.doi.org/10.1016/j.kjms.201Abstract This study aimed to identify the risk association between pioglitazone exposure
and bladder cancer. A nested caseecontrol study was performed using a representative data-
base randomly sampled from National Health Insurance enrollees. The source cohort consisted
of newly diagnosed diabetic patients from 1997 to 2009. Cases were identified as those with a
diagnosis of bladder cancer from 2002 to 2009. For each case, four matched control individuals
were randomly selected. A multiple logistic regression model was used to estimate the rela-
tive magnitude of risk in relation to the use of pioglitazone. In total, 259 cases and 1036 con-
trols were identified. The prevalent use of pioglitazone is similar in cases and controls
(adjusted odds ratio, 1.20; 95% confidence interval, 0.58e2.49). Compared to nonusers, these
values were 1.08 (0.41e2.88) for those with cumulative pioglitazone use  8268 mg and 1.35
(0.48e3.79) for those with cumulative pioglitazone use > 8268 mg. This study does not provide
support for the risk association between pioglitazone exposure and bladder cancer. Further
confirmation is needed due to the limitation of small case number with relatively shorter
exposure duration and lower cumulative dose.
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reserved.s have no conflicts of interest relevant to this article.
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Peroxisome proliferators-activated receptors (PPARs) are
ligand-activated transcription factors. PPARg has been
detected in normal urothelial cells and bladder tumors
[1,2]. Ligands for PPARg have been shown to alter cell
proliferation or differentiation in various cancer cell lines,
including urothelial cell carcinoma lines [3].
Pioglitazone, a thiazolidinedione, is a PPARg ligand used
in the treatment of type 2 diabetes mellitus. In the pre-
clinical studies, male rats (but not female rats or mice of
either sex) developed transitional cell neoplasms in the
bladder after 2 years of treatment with pioglitazone [4].
Experimental study also observed bladder tumors induced
by dual PPARa/PPARg agonists [5] and rosiglitazone, which
is another thiazolidinedione [6]. However, recent experi-
mental studies suggest that it might be a rat-specific phe-
nomenon [7].
There are limited data in humans to address this
question. The large PROactive (PROspective pioglitAzone
Clinical Trial In macroVascular Events) study observed a
nonsignificant excess of bladder neoplasm among patients
treated with pioglitazone [14 (0.5%) in the pioglitazone
group vs. 6 (0.2%) in placebo group] [8,9]. At the request
of the United States Food and Drug Administration, the
manufacturer is conducting a 10-year epidemiological
study. The 5-year interim analysis showed no overall sig-
nificant association between pioglitazone exposure and
bladder cancer. However, an increased risk of bladder
cancer was noted among patients with the longest
exposure and in those with the highest cumulative dose
[10].
Diabetes is prevalent and a large number of people use
antidiabetic agents on a long-term basis. Accompanying the
restricted use of rosiglitazone due to its cardiovascular risk,
the use of pioglitazone is increasing. The safety profile of
pioglitazone is of great concern. Using the National Health
Insurance (NHI) database, we conducted a nested
caseecontrol study to assess the risk association between
pioglitazone use and bladder cancer.
Methods
Data source
The NHI program, which provides compulsory universal
health insurance, was implemented in Taiwan on March 1,
1995 and covers over 98% of Taiwan’s population. In coop-
eration with the Bureau of NHI, the National Health
Research Institute (NHRI) sampled a representative data-
base of 1,000,000 individuals from the entire NHI enrollees
by means of a random sampling method for use in health
insurance-related studies. There were no statistically sig-
nificant differences in age, sex, and premium between the
sample group and all enrollees, as reported by the NHRI.
The data set includes all reimbursements (from Jan 1996 to
Dec 2009) for these 1,000,000 individuals.
Because the identification numbers of all individuals in
the NHRI databases were encrypted for protection of the
privacy of the sampled individuals, this study was exempt
from full review by the institutional review board.Identification of cases and control individuals
The source cohort consists of all incident diabetes patients
diagnosed during the period of 1997e2009. Diabetic pa-
tients were defined by the presence of two or more diag-
nostic codes for diabetes [International Classification of
Diseases, 9th revision, Clinical Modification (ICD-9-CM)
250.**] within 12 months in either inpatient or outpatient
service claim. Those with bladder cancer or other cancers
diagnosed prior to the diagnosis of diabetes and cases of
type 1 diabetes were excluded from the cohort. (In Taiwan,
patients with type 1 diabetes were registered as for cata-
strophic illness.) Once patients fulfilled the definition of
diabetic patients, the date of the first presence of ICD-9 for
diabetes was recognized as the reference date and patients
entered the cohort from then. Age was defined by the
reference date.
Pioglitazone was approved in Taiwan in June 2001 and
placed on the listing of NHI drug reimbursement in February
2002. From the source cohort, we identified cases as those
with new diagnoses of bladder cancer (ICD-9 188.**) from
2002 to 2009. We defined the date of diagnosis of bladder
cancer as the index date. Control individuals were matched
to the cases by sex, age, and time from entry into cohort to
the index date. In addition, they had no diagnosis of cancer
during this period of time. For each case, four control in-
dividuals were randomly selected from the set of all eligible
controls.
Information on pioglitazone exposure was extracted
from the prescription database. We defined pioglitazone
users as those with at least one prescription of pioglitazone
between diagnosis of diabetes and the index date. The date
of prescription, the daily dose, and the number of days
supplied were identified and cumulative doses (mg) were
calculated.
The potential confounders, including documented risk
factors for bladder cancer and comorbidities, were retrieved
by diagnostic codes. The ICD-9 codes for the confounders
were: nephropathy (580e589), urinary tract diseases
(590e599), urinary tract infection (590, 595, 597), urinary
tract stone (592, 594), hypertension (401e405), chronic
obstructive pulmonary disease (490e496), stroke (430e438),
ischemic heart disease (410e414), peripheral arterial dis-
eases (250.7, 785.4, 443.81, 440e448), eye disease (250.5,
362.0, 369, 366.41, 365.44), anddyslipidemia (272.0e272.4).Statistics
A conditional logistic regression model adjusting for all
potential confounders was used to estimate the relative
magnitude of risk in relation to the use of pioglitazone. The
participants were divided into three pioglitazone exposure
categories: nonusers, users of doses equal to or less than
the mean, and users of doses greater than the mean based
on the distribution of use among controls. Odds ratios (ORs)
and their 95% confidence intervals (CIs) were calculated
using patients with no exposure as reference. Analyses
were performed using the SAS statistical package (version
8.02; SAS Institute Inc., Cary, NC, USA). All statistical tests
were two-sided. A p value < 0.05 was considered statisti-
cally significant.
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The source cohort consisted of 64,745 newly-diagnosed
diabetic patients from 1997 to 2009. Among them, 262
patients developed bladder cancer from 2002 to 2009.
Three cases of bladder cancer were excluded because no
eligible control individuals could be found and leaving a
final total of 259 cases of bladder cancer, including 15 cases
with and 244 cases without pioglitazone use. A total of 1036
matched control individuals were randomly selected,
including 52 with and 984 without pioglitazone use.
Table 1 represents the demographic characteristics and
selected medical conditions of bladder cancer cases and
control individuals. Bladder cancer occurred at a higher
frequency in patients with nephropathy, urinary tract dis-
ease, urinary tract infection, and urinary tract stone.
The relationship between the use of pioglitazone and
bladder cancer is shown in Table 2. The prevalent use of
pioglitazone is similar in cases and controls. There is no
significant risk association between pioglitazone exposure
and bladder cancer after adjustment for potential con-
founders (OR, 1.20; 95% CI, 0.58e2.49). Compared to non-
users, the adjusted ORs (95% CI) were 1.08 (0.41e2.88) for
those with cumulative pioglitazone use  8268 mg and 1.35
(0.48e3.79) for those with cumulative pioglitazone
use < 8268 mg.Discussion
In this nested caseecontrol study, we did not observe a
significant association between pioglitazone exposure and
bladder cancer. However, we noted a nonsignificant OR of
up to 1.35 for those with high cumulative dose of pioglita-
zone. The safety of its long-term use still raised concern.
The data on the association between pioglitazone and the
risk of bladder cancer are limited and inconclusive. Earlier
data on safety come from the PROactive study, a randomized
controlled study including 2605 patients treated with pio-
glitazone and 2633 patients treated with placebo for the
investigation of cardiovascular outcome in patients with
type 2 diabetes and pre-existing cardiovascular disease.Table 1 Demographic characteristics of bladder cancer cases a
Variable Case (n Z 259
Age (y) 69.61  11.76
Female 99 (38.22)
Nephropathy 68 (26.25)
Urinary tract diseases 114 (44.02)
Urinary tract infection 29 (11.20)
Urinary tract stone 27 (10.42)
Hypertension 132 (50.97)
Chronic obstructive pulmonary disease 67 (25.87)
Stroke 43 (16.60)
Ischemic heart disease 56 (21.62)
Peripheral arterial disease 13 (5.02)
Eye disease 14 (5.41)
Dyslipidemia 22 (8.49)
Data are presented as mean  standard deviation or n (%).Although more cases of bladder neoplasm were observed
among patients treated with pioglitazone (0.5% vs 0.2%), the
study concluded that bladder cancer was not likely to be a
safety issue after excluding thosewith occurrence of bladder
cancerwithin 1 year of randomization,with benign histology,
and with known risk factors for bladder cancer [8,9]. The
interim report of a 10-year large cohort study using the
database of the Kaiser Permanente Northern California
health plan also showed no significantly increased risk of
bladder cancer in patients exposed to pioglitazone
compared to patients never exposed [hazard ratio (HR), 1.2;
95% CI, 0.9e1.5]. Notably, an increased risk was found in
those with more than 2 years of exposure (HR, 1.4; 95% CI,
1.03e2.0) [10]. A recent study using the Adverse Event
Reporting System database demonstrated an increased risk
of bladder cancer for pioglitazone use (reporting OR, 4.30;
95% CI, 2.82e6.52) [11]. In that study, the occurrence of
bladder cancer relied on a spontaneous reporting system and
notoriety bias is therefore possible. A retrospective cohort
study conducted in France using data from the French Na-
tional Health Insurance Plan also suggested an increased risk
of bladder cancer in patients exposed to pioglitazone (HR,
1.22; 95% CI, 1.03e1.43) [12,13].
The incidence of cancer and its risk factors differ among
different ethnicities. It has been shown that Caucasians have
more bladder cancer than other races. The cancer risk of
pioglitazone on Asians is rarely reported. Using randomly
sampled NHI database, Tseng [14] conducted a cohort study
defined by the year of 2006 and reported no significant as-
sociation between pioglitazone and bladder cancer. Our
study, by a nested caseecontrol approach, also showed
similar results. However, in contrast to Tseng’s study, we
found an OR of up to 1.35 for those with higher dose of pio-
glitazone exposure. The lower risk with higher cumulative
dose in Tseng’s study might be a chance effect. Although the
OR of 1.35 did not reach statistical significance, our study is
also limited by the small case number with insufficient
power. Further confirmation of this finding is required.
Our study has several strengths. First, the database is
population-based and highly representative. All newly
diagnosed diabetic patients from 1997 to 2009 were enrolled
in the source cohort, from which cases were identified andnd controls.
) Controls (n Z 1036) OR (95% CI)
69.60  11.70 0.9835
396 (38.22) 1.0000
181 (17.47) 1.68 (1.22e2.32)
245 (23.65) 2.54 (1.91e3.37)
76 (7.34) 1.59 (1.01e2.50)
53 (5.12) 2.16 (1.33e3.51)
440 (42.47) 1.41 (1.07e1.85)
354 (34.17) 0.67 (0.49e0.91)
208 (20.08) 0.79 (0.55e1.14)
199 (19.21) 1.16 (0.83e1.62)
61 (5.89) 0.85 (0.46e1.56)
30 (2.90) 1.92 (1.00e3.67)
89 (8.59) 0.99 (0.61e1.61)
Table 2 Associations between pioglitazone use and bladder cancer risk.
No. of cases /No. of controls Crude OR (95% CI) Adjusted ORa (95% CI)
Overall
No pioglitazone use 244/984 1.00 1.00
Any pioglitazone use 15/52 1.18 (0.60e2.30) 1.20 (0.58e2.49)
Cumulative use
0 244/984 1.00 1.00
0e8268 mg 8/32 1.21 (0.49e3.03) 1.08 (0.41e2.88)
8268 mg 7/20 1.14 (0.45e2.89) 1.35 (0.48e3.79)
p for trend 0.6759 0.5738
CI Z confidence interval; OR Z odds ratio.
a Adjusted for nephropathy, urinary tract diseases, urinary tract infection, urinary tract stone, hypertension, chronic obstructive
pulmonary disease, stroke, ischemic heart disease, peripheral arterial diseases, eye disease, and dyslipidemia.
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therefore avoided. Second, the computerized claim data-
base record all dispensed medication. The information on
the pioglitazone prescription is detailed and definite, so in-
formation bias is unlikely. Third, for a severe disease such as
bladder cancer, the diagnosis tends to be unequivocal and
the barrier for medical access is unlikely to be due to the
universal healthcare provided by the NHI program. The
possibility of misclassification is therefore low.
Some limitations of the present study should be noted.
First, some risk factors of bladder cancer, such as smoking,
hair dye use, family history, and occupational exposure, are
not available in the database. Adjustment of these vari-
ables in the statistical analysis is therefore impossible.
However, there is no reason to believe that there would be
any correlation between these confounders and use of
pioglitazone. Second, the pharmacy records represent
medication prescribed rather than consumed. Misclassifi-
cation of exposure would be possible if patients did not
take pioglitazone prescribed and the effects of pioglitazone
would be overestimated. Third, as an observational study,
residual confounding by unmeasured factors is still possible
even though many of the clinical conditions have been
considered as covariates in the statistical model. Finally,
the sample size is small and the cumulative dose of pio-
glitazone is relatively low compared to studies in Western
countries, which could result in undetectable association.
In conclusion, the present study cannot find an increased
risk of bladder cancer among patients treated with piogli-
tazone. A further large-scale study with a longer duration
of exposure and higher cumulative doses of pioglitazone is
needed to clarify this important issue.
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